-

ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial

SAN FRANCISCO & SYDNEY--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tools, today announced a strategic collaborative agreement with GenesisCare, an integrated cancer care provider.

The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding treatment decisions as part of a new clinical trial.

“We are honored to be able to partner with GenesisCare to provide the clinical community in Australia a way to personalize care for their patients,” said Andre Esteva, co-founder and CEO of ArteraAI.

ArteraAI and GenesisCare share a commitment to clinical innovation and advancing precision medicine, with the aim of improving the lives of patients with localized prostate cancer.

“Our research partnership with ArteraAI aligns with our aim to offer personalized and patient-centric care in communities across Australia,” said Professor Jarad Martin, GenesisCare Radiation Oncologist.

About ArteraAI

ArteraAI is a leading precision medicine company developing AI tools to personalize cancer therapy.

ArteraAI’s multimodal artificial intelligence (MMAI) biomarker tool leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient's clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis.

About GenesisCare Australia

GenesisCare is an integrated cancer care provider that aims to change the face of cancer care with modern treatments and techniques designed to achieve the best possible life outcomes for patients. In Australia, GenesisCare provides care to approximately 30,000 patients a year across 48 locations in metro and regional Victoria, New South Wales, Queensland, South Australia, and Western Australia. GenesisCare’s vision is to offer patients personalized, high-quality care throughout their cancer journey. For more information, visit www.genesiscare.com.

Contacts

Media:
Lesley Swiger
Antenna
artera@antennagroup.com
(202) 869-1612

Industry:

ArteraAI

Release Versions
English

Contacts

Media:
Lesley Swiger
Antenna
artera@antennagroup.com
(202) 869-1612

More News From ArteraAI

Artera Enrolls First Patient in DIRECT-AI Registry, Marking Milestone in Real-World Evidence Generation for AI-Powered Prostate Cancer Care

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the enrollment of the first patient in its DIRECT-AI registry study, marking the beginning of real-world prospective evidence generation for the first nationwide registry evaluating the clinical utility of an AI-powered prostate cancer test. The first patient was enrolled at The Urology Place, a leading independent urology practice in S...

CorePlus Integrates AI-Powered Prostate Cancer Risk Stratification Tool into its Digital Pathology Diagnostic Pathway — a First in Puerto Rico

SAN JUAN, Puerto Rico--(BUSINESS WIRE)--CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, announced today the integration of the ArteraAI Prostate Test into its diagnostic workflows, becoming the first laboratory in Puerto Rico to bring this guideline-recommended AI test into routine clinical use, allowing for fast and convenient delivery of treatment insights. The ArteraAI Prostate Test is an advanced risk stratification tool to help personalize and optimize tre...

Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the clinical availability of the ArteraAI Prostate Test (mHSPC), the first digital pathology–based prognostic test designed to help inform treatment planning for patients with metastatic hormone‑sensitive prostate cancer (mHSPC). mHSPC is a diverse disease state with widely variable outcomes, requiring complex treatment decisions that c...
Back to Newsroom